Overview: Plasma membrane located GABA transporters are members of the solute carrier family 6 (SLC6) of sodium-and chloride-dependent neurotransmitter transporters that includes the monoamine and glycine transporters (Chen et al., 2004). The members of this superfamily share a structural motif of 12 putative TM segments (Palacı´n et al., 1998). The activity of GABA-transporters located upon both neurones and glia serves to terminate GABA-ergic transmission, maintain low ambient extracellular concentrations of GABA, and recycle GABA for reuse by neurones and glia. A structurally and functionally distinct vesicular transporter representing the SLC32 family (VGAT/VIAAT (ENSG00000101438); McIntire et al., 1997; Sagne et al., 1997; Gasnier, 2004), subject to inhibition by vigabatrin, is responsible for concentrating GABA (and glycine) within synaptic vesicles. There is presently no recommendation from NC-IUPHAR concerning the nomenclature of GABA transporters. The nomenclature adopted here is that used for human GABA transporters. SNAP5114 is only weakly selective for GAT-3, with IC 50 values in the range 20 to 430 mM at GAT-1, GAT-2 and BGT-1, whereas NNC052090 has at least an order of magnitude selectivity for BGT-1 (see Schousboe et al., 2004b for a review). In addition to the inhibitors listed, EGYT3886 is a moderately potent, though nonselective, inhibitor of all cloned GABA transporters (IC 50 ¼ 26 -46 mM; Dhar et al., 1994). Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine that potently inhibit the uptake of [ 3 H]-GABA into rat synaptosomes have been described (Knutsen et al., 1999). Several derivatives of exo-THPO (e.g. N-methyl-exo-THPO and N-acetyloxyethyl-exo-THPO) demonstrate selectivity as blockers of astroglial, versus neuronal, uptake of GABA (see Schousboe et al., 2004a for a review). 
Overview: Plasma membrane located glutamate transporters (nomenclature as proposed by Amara & Arriza, 1993) transport both L-glutamate and L-asparate, and are members of the solute carrier family 1 (SLC1) of sodium-dependent transporters that also includes the neutral amino acid transporters ASCT1 and ASCT2 (Palacı´n et al., 1998; Kanai & Hediger, 2003) . Glutamate transporters present the unusual structural motif of 8TM segments and 1 (Seal et al., 2000) , or 2 (Grunwald & Kanner, 2000) , re-entrant loops. The recently determined crystal structure of a glutamate transporter orthologue from Pyrococcus horikosii supports the latter scheme and indicates that the transporter assembles as a trimer, where each monomer is a functional unit capable of substrate permeation (Yernool et al., 2004) , in agreement with the proposed quaternary structure for EAAT2 (Gendreau et al., 2004) . The activity of glutamate transporters located upon both neurones (predominantly EAAT3, 4 & 5) and glia (predominantly EAAT 1 & 2) serves, dependent upon their location, to regulate excitatory neurotransmission, maintain low ambient extracellular concentrations of glutamate (protecting against excitotoxicity) and provide glutamate for metabolism in the glutamate-glutamine cycle. In addition, a thermodynamically uncoupled Cl -flux, activated by Na þ and glutamate (Kanner & Borre, 2002; Kanai & Hediger, 2003; , is sufficiently large, in the instances of EAAT4 and EAAT5, to influence neuronal excitability. In the kidney, EAAT3 located in the apical membrane of proximal tubular cells is responsible for the reabsorption of glutamate (Hediger, 1999) . Three structurally and functionally distinct vesicular glutamate transporters (VGLUT1, 2 & 3) of the SLC17 family are responsible for concentrating glutamate within synaptic vesicles (Reimer & Edwards, 2004) .
The K b (or K i ) values reported in the table are derived from transporter currents mediated by EAATs expressed in voltage-clamped Xenopus laevis oocytes (Vandenberg et al., 1997; Shimamoto et al., 1998; Eliasof et al., 2001; Shigeri et al., 2001 ). K b (or K i ) values derived in uptake assays are generally higher (e.g. Shimamoto et al., 1998) . In addition to acting as a non-transportable inhibitor of EAAT2, (2S,4R)-4-methylglutamate, also known as SYM2081, is a competitive substrate for EAAT1 (K m ¼ 54 mM; Vandenberg et al., 1997) and is also a potent kainate receptor agonist (Zhou et al., 1997) . Similarly, at concentrations that inhibit EAAT2, dihydrokainate binds to kainate receptors (Shimamoto et al. 1998) . WAY-855 has recently been described as a non-transportable inhibitor with selectivity for EAAT1, versus EAAT2, or EAAT3 (Dunlop et al., 2003 (Eliasof et al., 2001) . In addition to the agents listed in the table, DL-threo-b-hydroxyaspartate and L-trans-2,4-pyrolidine dicarboxylate act as non-selective competitive substrate inhibitors of all EAATs. Zn 2 þ and arachidonic acid are putative endogenous modulators of EAATs with actions that differ across transporter subtypes (reviewed by Vandenberg et al., 2004) .
Glutamate (excitatory amino acid) 
Overview: Plasma membrane located glycine transporters (provisional nomenclature) are members of the solute carrier family 6 (SLC6) of sodium-and chloride-dependent neurotransmitter transporters that includes the monoamine and GABA transporters (Chen et al., 2004) . The members of this superfamily share a structural motif of 12 putative TM segments (Palacı´n et al., 1998) . Two gene products, GlyT1 and GlyT2, are known that give rise to transporters that are predominantly located on glia and neurones, respectively. Five variants of GlyT1 (a, b, c, e & f) differing in their N-and C-termini are generated by alternative promoter usage and splicing, and two splice variants of GlyT-2 (a & b) have also been identified (see Supplisson & Roux, 2002; Gomeza et al., 2003 for reviews) . GlyT1 transporter isoforms expressed in glia surrounding glutamatergic synapses regulate synaptic glycine concentrations influencing NMDA receptor-mediated neurotransmission (Bergeron et al., 1998) , but also are important in early neonatal life, regulating glycine concentrations at inhibitory glycinergic synapses (Gomeza et al., 2003a) . In addition, GlyT1 has been postulated to act as an organic osmolyte transporter important for cell volume regulation in cleavage-stage embryos (Steeves et al., 2003) . Homozygous mice engineered to lack GlyT1 exhibit severe respiratory and motor deficiencies due to hyperactive glycinergic signalling and die within the first postnatal day (Gomeza et al., 2003a; Tsai et al., 2004) . GlyT2 transporters localised on the axons and boutons of glycinergic neurones are likely to play a role in the termination of inhibitory neurotransmission and appear crucial for efficient transmitter loading of synaptic vesicles (Gomeza et al., 2003b) . Mice in which GlyT2 has been deleted develop a severe hyperekplexia phenotype during the second postnatal week and subsequently and die (Gomeza et al., 2003b Vandenberg et al., 2004) . Overview: Nucleoside transporters are divided into two families, the equilibrative, solute carrier family 29 (SLC29) and the sodium-dependent, solute carrier family 28 (SLC28), where the endogenous substrates are nucleosides. Structurally, SLC29 family members appear to be composed of 11 TM segments, while the SLC28 family have 13 TM segments, both with cytoplasmic N-termini and extracellular C-termini.
The affinities of draflazine, dilazep, KF24345 and dipyridamole at ENT1 transporters are species dependent, exhibiting lower affinity at rat transporters than at human transporters (Sundaram et al., 1998; Hammond & Archer, 2004 Hyde et al., 2001; Acimovic & Coe, 2002; Baldwin et al., 2004) .
A further two Na þ -dependent (1 : 1 Na þ stoichiometry) nucleoside transporters have been defined on the basis of substrate and inhibitor selectivity: CNT4 (N4/cit, which transports uridine, thymidine and guanosine) and CNT5 (N5/csg, which transports guanosine and adenosine, and may be inhibited by NBTI). 
